Retatrutide (LY3437943): Triple Agonist Research Guide

Retatrutide is an investigational peptide that activates three hormone receptors at once: GIP, GLP-1 and glucagon. That makes it one of the most closely followed molecules in metabolic research. This guide covers how it was designed, what laboratory studies show about its pharmacology, and where it stands in development.

What is retatrutide?

Retatrutide (development code LY3437943) is a synthetic, lipidated peptide developed by Eli Lilly and Company. Most incretin-based compounds act on one or two receptors. Retatrutide is a single molecule designed to act on three:

• GLP-1R: the glucagon-like peptide-1 receptor, the target of the first generation of incretin compounds
• GIPR: the glucose-dependent insulinotropic polypeptide receptor
• GCGR: the glucagon receptor

Why three receptors?

The discovery paper, published in Cell Metabolism in 2022, describes the design reasoning [1]. In cell-based assays, LY3437943 showed balanced activity at the glucagon and GLP-1 receptors and greater activity at the GIP receptor.

In obese mouse models, the authors attributed the compound’s effects to two complementary mechanisms. GIPR and GLP-1R activity reduced calorie intake, while GCGR activity added an increase in energy expenditure. Glucagon-receptor activity is the piece that sets retatrutide apart from dual GIP/GLP-1 agonists, which is why the receptor-balance data draw so much research interest.

Pharmacology highlights from the discovery work

• Receptor profile: stronger at GIPR than at GCGR or GLP-1R, with GCGR and GLP-1R activity roughly balanced [1].
• Half-life engineering: a fatty-acid side chain helps the peptide bind albumin, which prolongs its circulation. Its pharmacokinetic profile supported a once-weekly interval in early clinical work [1].
• Adipocyte research: a published laboratory protocol describes using human subcutaneous adipocytes to measure lipolysis induced by GIP or LY3437943, a useful reference for in-vitro work [2].

Where retatrutide stands in development

Retatrutide has moved through Phase 2 studies into a Phase 3 program known as TRIUMPH. Results have been published in journals including The New England Journal of Medicine and The Lancet [3–5]. The design of the registrational trials is described in Diabetes, Obesity and Metabolism [6]. As of this writing, retatrutide is not approved by the FDA or any other regulator.

We report its development status for context only. Ares Labs supplies retatrutide for in-vitro and preclinical laboratory research. We make no claims about its effects in people.

Laboratory handling

• Lipidated peptides can behave differently in solution than short unmodified peptides. Use the solubility and storage notes on the product label and COA.
• Store lyophilized material cold, dry and away from light, and log lot numbers for traceability.
• Confirm identity and purity against the batch Certificate of Analysis before beginning an experiment.

FAQ

Is retatrutide FDA-approved?
No. Retatrutide is an investigational compound and is not approved for any use. Ares Labs sells it for laboratory research only.

How is retatrutide different from tirzepatide or semaglutide?
Semaglutide targets GLP-1R, and tirzepatide targets GIPR and GLP-1R. Retatrutide adds glucagon-receptor agonism, making it a triple agonist.

What amounts do you carry?
See the retatrutide product page for current vial amounts, pack sizes and the latest COA.

View retatrutide research vials and the current COA →

References

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247. PMID 35985340
2. Regmi A, et al. Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943. STAR Protoc. 2023. PMID 37178114
3. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315
4. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. Lancet. 2023. PMID 37385280
5. Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a phase 3 trial. Lancet. 2026. PMID 42810372
6. Giblin K, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026. PMID 41090431

For laboratory research use only. Not for human or animal consumption. This article summarizes published research for reference. It is not medical advice and makes no claim that any product treats, cures or prevents any condition.